Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease

Jeffrey A. Kaye, Conrad May, John R. Atack, Eileen Daly, Daniel L. Sweeney, M. Flint Beal, Seymour Kaufman, Sheldon Milstien, Robert P. Friedland, Stanley I. Rapoport

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin‐like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age‐matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterin were significantly Decemberreased. 5‐Hydroxyindole‐acetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower than in control subjects. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results, suggest that DAT patients with myoclonus represent a distinct clinical and neurochemical DAT subtype.

Original languageEnglish (US)
Pages (from-to)647-650
Number of pages4
JournalAnnals of Neurology
Volume24
Issue number5
DOIs
StatePublished - Nov 1988

    Fingerprint

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Kaye, J. A., May, C., Atack, J. R., Daly, E., Sweeney, D. L., Flint Beal, M., Kaufman, S., Milstien, S., Friedland, R. P., & Rapoport, S. I. (1988). Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Annals of Neurology, 24(5), 647-650. https://doi.org/10.1002/ana.410240509